None listed
Conditions
Brief summary
The primary purpose of this study is to identify biological markers in tumour and blood samples which may predict clinical outcomes and response to treatment in prostate cancer patients. Who is it for?: You may be eligible to participate in this study if you are aged 18 or over, with a diagnosis of prostate cancer of which a tumour specimen has already been taken and is available for further testing. Study details: All participants in this study will have a small sample of their tissue (primary and metastatic) that was taken at diagnosis used for research. Researchers will look at the DNA inside the tissue and see if they can find any 'markers' that may make patients respond better to certain types of treatments. A blood sample will also be taken at the start and at the end end of any treatment you may have. Researchers will also use medical records to correlate any biological markers with disease outcomes. It is hoped that the findings of this study will lead to the identification and validation of biological markers which may allow more personalised treatment for future prostate cancer patients.
Interventions
Enrolled patients will undergo collection of clinical data and tumour and blood specimens, as well as any archival tissue that is available. For those patients who undergo a planned resection or biopsy of a “current” metastatic tumour specimen, a sample will be collected from residual tissue that contains tumour – this is referred to as fresh tissue.
Patients that consent to the “liquid biopsy” (blood collection) will undergo collection of blood at the beginning and end of each systemic therapy
Enrolled patients will undergo collection of clinical data and tumour and blood specimens, as well as any archival tissue that is available. For those patients who undergo a planned resection or biopsy of a “current” metastatic tumour specimen, a sample will be collected from residual tissue that contains tumour – this is referred to as fresh tissue. Patients that consent to the “liquid biopsy” (blood collection) will undergo collection of blood at the beginning and end of each systemic therapy. Archival tumour specimens and “current” fresh biopsy tumour specimens will be stored at designated site-specific laboratories. Blood products will be stored frozen in a -70C at designated site-specific laboratories. Enrolled patients will have clinical data collected for the life of the project or until patient death. This may range between 1 to 10 years dependent on when the patient enrolls.
Sponsors
Walter and Eliza Hall Institute
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age >18 years 2. Histological or cytological diagnosis of prostate cancer 3. Archival tumour specimen is available for molecular analysis 4. Able to be accessible for follow-up and data collection 5. Written, voluntary and informed consent for biopsy 6. Able to undergo core needle biopsy of metastases (patients must have a lesion which is deemed medically safe to biopsy) 7. Written, voluntary and informed consent for blood collection 8. Able to undergo collection of blood specimen at the beginning of each new systemic therapy
Exclusion criteria
1. No archival tumour is specimen available for molecular analysis 2. Unable to be accessible for follow-up and data collection
Outcome results
None listed